keyword
MENU ▼
Read by QxMD icon Read
search

muscle invasive urothelial bladder cancer

keyword
https://www.readbyqxmd.com/read/28633191/-urothelial-cancer-update-on-systemic-treatment-options
#1
Günter Niegisch
Perioperative chemotherapy is likely to improve survival in both the neoadjuvant and the adjuvant setting. Therefore, it is an integral part of the modern treatment of patients with muscle-invasive urothelial bladder cancer. All patients who are suitable for cisplatin-based chemotherapy should be involved in a corresponding concept.Cisplatin-based combinations are standard regimens in the perioperative and palliative systemic treatment of urothelial cancer. Carboplatin is only an inferior substitute for "unfit" patients in the palliative treatment situation...
June 20, 2017: Aktuelle Urologie
https://www.readbyqxmd.com/read/28628011/-criteria-for-selection-of-tumor-cells-and-prospects-for-specific-immunotherapy-for-bladder-cancer
#2
T Slavyanskaya, S -Salnikova, R Sepiashvili
Specific antitumor immunotherapy with autologous dendritic cell vaccines is one of the new approaches of modern medicine. For activation of dendritic cells highly immunogenic antigens are used, however optimal antigens in case of bladder cancer (BC) are still not researched. Cancer-testis antigens (CTA) are the most promising target in the context of creation of antitumor vaccines, because they are distinguished by pronounced immunogenicity, they are detected in different types of tumors and have limited pattern of expression in healthy tissues of grown-up organism...
May 2017: Georgian Medical News
https://www.readbyqxmd.com/read/28627636/formulation-and-characterization-of-egcg-for-the-treatment-of-superficial-bladder-cancer
#3
Katarzyna Dettlaff, Maciej Stawny, Magdalena Ogrodowczyk, Anna Jelińska, Waldemar Bednarski, Dorota Wątróbska-Świetlikowska, Rick W Keck, Omar A Khan, Ibrahim H Mostafa, Jerzy Jankun
In the United States, the annual incidence of bladder cancer is approximately 70,000 new cases, with a mortality rate of approximately 15,000/year. The most common subtype (70%) of bladder cancer is superficial, namely hte non-muscle invasive disease form limited to the urothelium. The rate of progression and recurrence is up to 40 and 70%, respectively. Urothelial cell carcinoma of the bladder is typically treated with transurethral resection. The cancerous cells can float onto the adjacent epithelium, increasing the risk of recurrence...
June 14, 2017: International Journal of Molecular Medicine
https://www.readbyqxmd.com/read/28623648/systemic-chemotherapy-in-muscle-invasive-and-metastatic-bladder-cancer-present-and-future
#4
Gabriella Del Bene, Cora N Sternberg
Bladder cancer is the most frequent among the urothelial tumors, and it is responsible for about 2% of all cancer mortality worldwide. The mainstay of chemotherapy treatment, both for muscle-invasive and metastatic disease, is cisplatin-based regimens. In recent years, ground-breaking results have been achieved with immunotherapy, which have led to important breakthroughs in the bladder cancer treatment scenario, with the approval of several new agents. New insights derive from a greater characterization of the tumor genome, which could lead to developing new therapies, more personalized, in the near future...
June 14, 2017: Urologia
https://www.readbyqxmd.com/read/28618711/re-eortc-nomograms-and-risk-groups-for-predicting-recurrence-progression-and-disease-specific-and-overall-survival-in-non-muscle-invasive-stage-ta-t1-urothelial-bladder-cancer-patients-treated-with-1-3-years-of-maintenance-bacillus-calmette-gu%C3%A3-rin
#5
https://www.readbyqxmd.com/read/28600686/a-critical-prognostic-analysis-of-neutrophil-lymphocyte-ratio-for-patients-undergoing-nephroureterectomy-due-to-upper-urinary-tract-urothelial-carcinoma
#6
Mesut Altan, Hakan Bahadır Haberal, Bülent Akdoğan, Haluk Özen
BACKGROUND: To determine preoperative serum complete blood count parameters that affects survival of patients who underwent surgery for upper urinary tract urothelial cancer (UUT-UC). METHODS: Since 1990, 150 patients underwent nephroureterectomy with bladder cuff excision for UUT-UC at Hacettepe University. Patients with a history of muscle-invasive bladder cancer, adjuvant chemotherapy or metastasis at the time of diagnosis were excluded. One hundred and thirteen patients without infective symptoms and with a full set of serum data were evaluated retrospectively...
June 9, 2017: International Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28586118/a-dna-hypermethylation-profile-reveals-new-potential-biomarkers-for-the-evaluation-of-prognosis-in-urothelial-bladder-cancer
#7
Jose I López, Javier C Angulo, Ana Martín, Manuel Sánchez-Chapado, Ana González-Corpas, Begoña Colás, Santiago Ropero
DNA hypermethylation has emerged as a molecular biomarker for the evaluation of cancer diagnosis and prognosis. We define a methylation signature of bladder cancer and evaluate whether this profile assesses prognosis of patients. Genome-wide methylation analysis was performed on 70 tumor and 10 normal bladder samples. Hypermethylation status of 1505 CpGs present in the promoter region of 807 genes was studied. Thirty-three genes were significantly hypermethylated in ≥10% of the tumors. Three clusters of patients were characterized by their DNA methylation profile, one at higher risk of dead of disease (p = 0...
June 6, 2017: APMIS: Acta Pathologica, Microbiologica, et Immunologica Scandinavica
https://www.readbyqxmd.com/read/28580540/updates-for-the-radiologist-in-non-muscle-invasive-muscle-invasive-and-metastatic-bladder-cancer
#8
REVIEW
Jooae Choe, Marta Braschi-Amirfarzan, Sree Harsha Tirumani, Atul B Shinagare, Kyung Won Kim, Nikhil H Ramaiya, Katherine M Krajewski
Urothelial bladder cancer is a common malignancy requiring a multidisciplinary approach to treatment. Significant recent advances have been made in terms of the genetic and molecular characterization of bladder cancer subtypes, and novel treatment approaches are being investigated and approved. Given the important role of imaging in the diagnosis, staging, and follow-up of this disease, it is necessary for radiologists to remain up-to-date in terms of nomenclature and standards of care. In this review, recent developments in bladder cancer characterization and treatment will be discussed, with reference to the contributions of imaging in non-muscle-invasive, muscle-invasive, and metastatic settings...
June 3, 2017: Abdominal Radiology
https://www.readbyqxmd.com/read/28578357/is-survival-after-radical-cystectomy-for-bladder-cancer-in-saudi-patients-different-from-that-of-western-patients
#9
Alaa Mokhtar, Mohamed Matar Al, Waleed Mohamad Al, Khalid Al Othman, Said A Kattan, Mohammed Faihan Al
BACKGROUND: Although radical cystectomy (RC) is considered the gold standard treatment of muscle invasive bladder cancer, nearly half of patients develop metastases and ultimately die within 2 years. OBJECTIVE: To assess survival, evaluate different prognostic factors that may affect disease-free survival (DFS) in Saudi patients after RC for carcinoma of the bladder and to compare our results with those of Western countries. DESIGN: Retrospective chart review...
May 2017: Annals of Saudi Medicine
https://www.readbyqxmd.com/read/28540249/liquid-biopsies-for-bladder-cancer
#10
EDITORIAL
Douglas G Ward, Richard T Bryan
The development of accurate urinary biomarkers for the non-invasive detection of urothelial bladder cancer (UBC) could transform patient pathways by reducing reliance on cystoscopy, and the identification of highly prognostic (or even predictive) biomarkers could better guide patient management. A number of approaches are being utilised to address these challenges in both urinary- and plasma-borne tumour DNA (tDNA), so-called "liquid biopsies". Next generation sequencing (NGS) and droplet digital PCR (ddPCR) allow detection of very low levels of such tDNA amongst a large excess of non-tumour DNA, the former permitting large mutation panels to be assessed and the latter potentially identifying ultrarare mutant alleles yet restricted for multiplexing...
April 2017: Translational Andrology and Urology
https://www.readbyqxmd.com/read/28533583/high-grade-urothelial-carcinoma-of-bladder-transforming-to-micropapillary-variant-on-follow-up
#11
Nitu Kumari, Anupama Jha, Pawan Vasudeva, Usha Agrawal
Micropapillary variant of urothelial carcinoma (UC) of the bladder is an aggressive tumour, comprising 0.6-6% of all UC. It generally presents with high-grade and stage, and has been reported as having a worse prognosis when compared to traditional UC. We report the case of a 58-year-old man who presented with macroscopic haematuria. The patient was diagnosed with high-grade urothelial carcinoma and returned with recurrence after 16 months. Histopathology after transurethral biopsy revealed a non-muscle invasive high-grade bladder tumour at first presentation, whereas tumour recurrence was reported after 1...
May 2017: Iranian Journal of Medical Sciences
https://www.readbyqxmd.com/read/28529600/prospective-evaluation-of-fluorescence-in-situ-hybridization-for-diagnosing-urothelial-carcinoma
#12
Tianhai Lin, Zhenhua Liu, Liangren Liu, Lu Yang, Ping Han, Peng Zhang, Qiang Wei
Urothelial carcinoma (UC) is the most common type of cancer of the bladder and upper urinary tract, and is characterized by a high risk of recurrence and progression. Urine fluorescence in situ hybridization (FISH) is a technique that detects genetic aberrations in exfoliated cells in the urine, with specific probes for chromosomes 3, 7 and 17 and the p16 gene. To evaluate the diagnostic value of FISH in UC, 119 patients from November 2010 to June 2012 with suspected UC were recruited into a prospective, cross-sectional study and were followed up for 12-30 months...
May 2017: Oncology Letters
https://www.readbyqxmd.com/read/28505892/re-oncologic-outcomes-of-kidney-sparing-surgery-versus-radical-nephroureterectomy-for-upper-tract-urothelial-carcinoma-a-systematic-review-by-the-eau-non-muscle-invasive-bladder-cancer-guidelines-panel
#13
https://www.readbyqxmd.com/read/28504717/fibulin-3-promotes-muscle-invasive-bladder-cancer
#14
A L Han, B A Veeneman, L El-Sawy, K C Day, M L Day, S A Tomlins, E T Keller
Urothelial carcinoma is the most common type of bladder cancer and can be categorized as either non-muscle-invasive (Ta-T1) or muscle-invasive (⩾T2). The majority of bladder cancers are non-muscle-invasive at presentation; however, the recurrence rate for these tumors is high and a subset can progress to T2. In this study, we aimed to identify genes differentially expressed between T1 vs T2 bladder cancer to identify key regulators of bladder cancer progression and/or invasion. We performed RNA-Seq on T1 and T2 bladder cancer tissues and used publicly available bladder cancer profiling studies to prioritize differentially expressed genes for validation and functional assessment...
May 15, 2017: Oncogene
https://www.readbyqxmd.com/read/28498805/foxm1-predicts-overall-and-disease-specific-survival-in-muscle-invasive-urothelial-carcinoma-and-presents-a-differential-expression-between-bladder-cancer-subtypes
#15
Sebastien Rinaldetti, Ralph Markus Wirtz, Thomas Stefan Worst, Markus Eckstein, Cleo Aaron Weiss, Johannes Breyer, Wolfgang Otto, Christian Bolenz, Arndt Hartmann, Philipp Erben
Forkhead box M1 (FOXM1) is a late cell cycle gene that plays a crucial role in carcinogenesis and chemotherapeutic drug resistance. In this study, the impact of FOXM1 expression on patient outcome was investigated for the first time in formalin fixed and paraffin embedded (FFPE) samples of chemotherapy naïve muscle-invasive bladder cancer (MIBC) patients. Expression analyses were performed on the Mannheim cohort (n=84) and validated on the independent Chungbuk cohort (n=61). In a Cox' proportional hazards model, a distinct FOXM1 expression cut-off dividing both cohorts in a 'high-risk' and 'low-risk' group has been determined...
April 24, 2017: Oncotarget
https://www.readbyqxmd.com/read/28494780/metastatic-non-muscle-invasive-bladder-cancer-with-meningeal-carcinomatosis-case-report-of-an-unexpected-response
#16
Diego Teyssonneau, Amaury Daste, Vincent Dousset, Jean-Luc Hoepffner, Alain Ravaud, Marine Gross-Goupil
BACKGROUND: Non-muscle invasive bladder cancer (NMIBC) is usually treated with local therapy including transurethral resection of the bladder tumor and intravesical therapy depending on the stage of the tumor. NMIBC is a rarely a metastatic diseases with lymph node invasion in less of 10%. In the other hand meningeal carcinomatosis is a rare location for metastases with extremely poor outcomes. We described a case report of a patient presenting a metastatic disease to bones and meninges, several years after the treatment of NMIBC, which had been in complete response (CR) for 4 years after chemotherapy treatment...
May 11, 2017: BMC Cancer
https://www.readbyqxmd.com/read/28493171/immunotherapy-in-urothelial-cancer-recent-results-and-future-perspectives
#17
REVIEW
Matthew S Farina, Kevin T Lundgren, Joaquim Bellmunt
Cytotoxic chemotherapy has been the only systemic treatment of locally advanced and metastatic urothelial carcinoma for decades. Long-term survival remains stagnant around 12-14 months for patients with advanced disease who have progressed on or recurred after receiving first-line platinum-based chemotherapy. Improving clinical outcomes for patients with urothelial carcinoma in all disease settings requires the development of novel treatments, especially for patients who failed on first-line chemotherapy. Since the discovery of intravesical Bacillus-Calmette Guerin (BCG) in the 1970s for non-muscle invasive disease, there have not been any major breakthrough drugs that exploit the immune-sensitivity of bladder cancer until recently...
May 11, 2017: Drugs
https://www.readbyqxmd.com/read/28489981/evolving-treatment-of-advanced-urothelial-cancer
#18
Srikala S Sridhar
Urothelial cancer of the bladder is a smoking-related cancer and the fifth most common cancer in the United States. At presentation, up to 25% of patients will have muscle-invasive disease and, despite cystectomy or bladder-sparing trimodality approaches, will develop metastatic disease. Cisplatin-based combination chemotherapy regimens remain the standard of care in first-line metastatic disease. Although response rates to these regimens are high, they are rarely durable, and median overall survival is only 12 to 15 months...
May 2017: Journal of Oncology Practice
https://www.readbyqxmd.com/read/28487492/sequencing-of-cancer-cell-subpopulations-identifies-micrometastases-in-a-bladder-cancer-patient
#19
Kris Prado, Kelvin X Zhang, Matteo Pellegrini, Arnold I Chin
PURPOSE: Pathologic staging of bladder cancer patients remains a challenge. Standard-of-care histology exhibits limited sensitivity in detection of micrometastases, which can increase risk of cancer progression and delay potential adjuvant therapies. Here, we sought to develop a proof of concept novel molecular approach to improve detection of cancer micrometastasis. EXPERIMENTAL DESIGN: We combined fluorescence activated cell sorting and next-generation sequencing and performed whole-exome sequencing of total cancer cells and cancer cell subpopulations in multiple tumor specimens and regional lymph nodes in a single patient with muscle-invasive urothelial carcinoma of the bladder following radical cystectomy...
April 21, 2017: Oncotarget
https://www.readbyqxmd.com/read/28481707/immune-checkpoint-blockade-in-metastatic-urothelial-cancer
#20
Arjun Vasant Balar
The Oncology Grand Rounds series is designed to place original reports published in the Journal into clinical context. A case presentation is followed by a description of diagnostic and management challenges, a review of the relevant literature, and a summary of the authors' suggested management approaches. The goal of this series is to help readers better understand how to apply the results of key studies, including those published in Journal of Clinical Oncology, to patients seen in their own clinical practice...
May 8, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
keyword
keyword
105932
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"